Akura Medical’s Post

Insight Lifetech Co., Ltd. , a portfolio company of Qiming Venture Partners, has received Class III medical device registration approval from China's National Medical Products Administration for its innovative TrueExtensio® Ultimate Balloon-Expandable Catheter. TrueExtensio® Ultimate is the world's first balloon-expandable catheter designed for exceptional support and anchoring. It provides superior stability by securely fixing the extension catheter in place within the blood vessel, improving both device delivery and vascular access. With a tapered tip and ultra-smooth hydrophilic coating, the catheter minimizes the risk of vessel wall injury, while its flexible dual-imaging technology ensures excellent visibility for precise and efficient navigation. #MedicalInnovation #TrueExtensio #VascularHealth #MedicalDevices #HealthcareTechnology #QimingPortfolio #QimingHealthcare

Shukun Technology, a portfolio company of Qiming Venture Partners, has achieved a significant milestone with the approval of its coronary calcium scoring assessment software CaScoreDoc as a Class III medical device by China's National Medical Products Administration (NMPA). This latest certification further strengthens Shukun Technology's "Digital Heart" product portfolio, which already includes Class III approvals for its Careverse Coronary Doc and Careverse FFR products. These advancements underscore the company's commitment to innovation and leadership in medical imaging and AI-driven diagnostics. The newly approved calcium scoring software leverages Shukun Technology's proprietary AI technology to analyze non-gated chest CT scans, accurately calculating calcium scores with consistency comparable to gated methods. By automating the identification and scoring of coronary calcification areas, the software significantly enhances the precision of early coronary artery disease screening and assessment. #HealthcareInnovation #MedicalImaging #DigitalHealth #AIinHealthcare #CardiovascularHealth #QimingPortfolio #QimingHealthcare

🏥 4C Medical Technologies, Inc. commenced enrolment in its ATLAS pivotal trial evaluating its AltaValve transcatheter mitral valve replacement (TMVR) technology to address mitral regurgitation, which can lead to heart failure or death if untreated. 👏 "We are very grateful for such strong support from key opinion leaders worldwide who are helping us carry our novel AltaValve System through pivotal trial with a goal of delivering safe and effective treatment solution for patients suffering from MR,” said Saravana Kumar, CEO and President at 4C Medical. 🔗 Learn more: https://lnkd.in/dbC3gYjc 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dbRqZCMi #MedicalDevices #MedicalDevice #MedicalEquipment #HealthTech #GuidedSolutions #ExecutiveSearch

This morning our Head of Research Colin Smith initiated coverage 📓 of Polarean (LSE: POLX). Despite initial FDA approval and grant of the requisite reimbursement codes, investor confidence in #POLX is low, as reflected in the current share price. However, revenue growth is already accelerating and is set to go hyperbolic as Polarean’s Xenon MRI platform meets a large unmet clinical need that cannot be satisfied by other methods. Crossing the bridge to profitability will require additional funding but there is a cash runway through 1Q26. Polarean has potential upside many times its current market cap, we calculate, based on observable deal metrics and our NPV analysis, while the valuation is so low, it could attract take-over interest, we believe. The purpose of AIM-listed Polarean is to revolutionise pulmonary medicine through direct visualisation of lung function, thereby radically improving patient care. You can read the full note below or on our portal: https://lnkd.in/e6BWF_iM #Research #Equities #UKEquities #AIM #investmentresearch #healthcare #LungMRI #PulmonaryImaging #XenonMRI #AdvancedDiagnostics

How do your patients cope with changes in therapy dose during their daily activities? Thanks to its innovative closed-loop technology Inceptivᵀᴹ SCS allows your patients to maintain a consistent therapy during daily activities †. In addition, Inceptivᵀᴹ is the only device that offers therapy optimization with multiple waveforms flexibility. Inceptiv™ SCS is only approved in Europe and Japan. †Sensing signals may not be measurable in all cases. #MedtronicEmployee

During #TCT2024, Dr. Sanjaya Gupta presented the ReliaSeal clinical study results comparing the safety & efficacy of MYNX CONTROL™ VENOUS VCD and manual compression. Learn more about the study results here - https://lnkd.in/eSdxTiNK #CordisGoBeyond #MoveForwardWithMYNX #EP

How do your patients cope with changes in therapy dose during their daily activities? Thanks to its innovative closed-loop technology Inceptivᵀᴹ SCS allows your patients to maintain a consistent therapy during daily activities †. In addition, Inceptivᵀᴹ is the only device that offers therapy optimization with multiple waveforms flexibility. Inceptiv™ SCS is only approved in Europe and Japan. †Sensing signals may not be measurable in all cases. #MedtronicEmployee

We’re excited to announce that InterMed Medical ANZ will become the exclusive distributor of the Olympus Surgical Energy Devices* (SED) portfolio in New Zealand, from Monday 2nd December! InterMed has been a trusted partner in distributing Olympus ENT products in New Zealand, and we’re confident they will continue to provide the same exceptional support and expertise for the SED portfolio. To learn more about this partnership, visit: https://lnkd.in/gPfrBJ4c. We look forward to combining our expertise with InterMed with the aim to facilitate positive outcomes for both clinicians and patients. #InterMedMedical #Olympus #SurgicalEnergyDevices #Partnership *Olympus products are not available for purchase by the general public and must be administered by a Healthcare Professional.

You are a phlebologist? You are an edema specialist? And, you want to improve the quality of your next clinical study? Here is the perfect tool for you: Accutrack® by SIGVARIS GROUP. No more doubts about the reliability of your patient questionnaires. Accutrack® is the first sensor that provides an objective measurement of compliance. For more check out https://lnkd.in/di8kj28y or send an email to accutrack@sigvaris.com. Latest results published in Phlebology. 2024 Apr;39(3):194-201. https://lnkd.in/dWdrGdYR #sigvarisgroup #accutrack #feelyourbest #everyday #compressiongarment #compliance #patientjourney

How do your patients cope with changes in therapy dose during their daily activities? Thanks to its innovative closed-loop technology Inceptivᵀᴹ SCS allows your patients to maintain a consistent therapy during daily activities †. In addition, Inceptivᵀᴹ is the only device that offers therapy optimization with multiple waveforms flexibility. Inceptiv™ SCS is only approved in Europe and Japan. †Sensing signals may not be measurable in all cases. #MedtronicEmployee